<p>Ensign Peak Advisors Inc 在第二季度减持了 Moderna, Inc.（纳斯达克股票代码: MRNA - 免费报告）的持股比例，根据最近提交给证券交易委员会的文件显示，该公司持有该公司股票 73,064 股，较上一季度减持了 80,198 股。Ensign Peak Advisors Inc 在最近季度结束时持有的 Moderna 股份价值 867.6 万美元。</p>
<ul>
<li>3 支备受打击的股票准备复苏</li>
</ul>
<p>其他几家机构投资者也买入和卖出了 MRNA 的股票。Hobbs Group Advisors LLC 在第四季度购入了 Moderna 的新头寸，价值 66.4 万美元。伊利诺伊州市政退休基金在第一季度增持了 Moderna 的持股比例 22.1%。伊利诺伊州市政退休基金现在持有该公司股票 51,791 股，价值 551.9 万美元，较上一季度增持了 9,360 股。瑞典银行 AB 在第一季度购入了 Moderna 的新头寸，价值约 331.5 万美元。惠灵顿管理集团 LLP 在第四季度增持了 Moderna 的股份 28.8%。惠灵顿管理集团 LLP 现在持有该公司股票 7,225,579 股，价值 7.19 亿美元，较上一季度增持了 1,614,460 股。最后，洛杉矶资本管理有限责任公司在第一季度购入了 Moderna 的新股份，价值约 269.3 万美元。对冲基金和其他机构投资者拥有该公司股份的 75.33%。</p>
<h2>分析师的升级和下调</h2>
<p>MRNA 近期成为多份研究报告的主题。杰富瑞金融集团将 Moderna 的股票评级从 “买入” 下调至 “持有”，并将公司的目标股价从 120.00 美元降至 65.00 美元。摩根大通将 Moderna 的评级从 “中性” 下调至 “减持”，并将公司的目标股价从 88.00 美元降至 70.00 美元。美国银行将 Moderna 的目标股价从 130.00 美元降至 110.00 美元，并为该公司设定了 “持有” 评级。Oppenheimer 将 Moderna 的评级从 “表现优异” 下调至 “市场表现”，德意志银行将 Moderna 的股票评级从 “卖出” 上调至 “持有”，并将公司的目标股价从 85.00 美元降至 80.00 美元。两位投资分析师给该股票评定了卖出评级，十三位分析师给予持有评级，四位分析师给予买入评级。根据 MarketBeat.com 的数据，Moderna 目前的平均评级为 “持有”，股票的共识目标价为 100.44 美元。</p>
<ul>
<li>Moderna 最近的下跌：看涨者看到机会</li>
</ul>
<p><strong>查看我们对 MRNA 的最新分析</strong></p>
<h2>Moderna 股票表现</h2>
<p>纳斯达克 MRNA 股票周三开盘价为 63.94 美元。该股票的 50 天移动平均价格为 87.70 美元，200 天移动平均价格为 110.43 美元。该股票的市值为 245 亿美元，市盈率为-4.08，β系数为 1.67。Moderna, Inc.的一年最低价为 62.55 美元，最高价为 170.47 美元。该公司的流动比率为 4.09，速动比率为 3.92，负债权益比为 0.05。</p>
<ul>
<li>GeoVax Labs：这家微型生物技术公司是繁荣还是衰败？</li>
</ul>
<p>Moderna（纳斯达克股票代码: MRNA - 获取免费报告）最近公布了其截至 8 月 1 日星期四的季度财报。公司报告称，该季度每股亏损 3.33 美元，超过分析师预期的 3.47 美元，增加了 0.14 美元。Moderna 的净利润率为-116.18%，净资产收益率为-21.35%。该季度，公司营收为 2.41 亿美元，而分析师预计为 1.2841 亿美元。与去年同期相比，公司季度营收同比下降了 29.9%。卖方分析师预计，Moderna, Inc.在本财年将实现每股盈利-9.52 美元。</p>
<h2>Moderna 内部人员的买卖行为</h2>
<p>另外，总裁 Stephen Hoge 于 7 月 15 日星期一出售了 15,000 股公司股票。股票的平均价格为 121.12 美元，总价值为 1,816,800.00 美元。完成交易后，总裁现在持有该公司股票 1,442,089 股，价值约 1.75 亿美元。该交易已在提交给 SEC 的文件中披露，可通过此超链接查看。此外，首席财务官 James M. Mock 于 7 月 8 日星期一出售了 689 股公司股票。股票的平均价格为 118.24 美元，总价值为 81,467.36 美元。交易完成后，首席财务官现在持有公司 7,269 股股票，价值 85.9 万美元。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。此外，总裁 Stephen Hoge 于 7 月 15 日星期一出售了 15,000 股公司股票。股票的平均价格为 121.12 美元，总交易额为 1,816,800.00 美元。交易完成后，总裁现在持有该公司股票 1,442,089 股，价值 1.75 亿美元。此次交易的披露可在此处找到。内部人士在过去三个月内共出售了总值 925.9 万美元的 78,158 股公司股票。公司内部人士持有公司股份的比例为 15.70%。</p>
<h2>关于 Moderna（免费报告）</h2>
<p>Moderna, Inc.是一家生物技术公司，致力于发现、开发和商业化信使 RNA 治疗药物和疫苗，用于治疗传染病、免疫肿瘤学、罕见疾病、自身免疫性疾病和心血管疾病，在美国、欧洲和国际市场均有业务。其呼吸道疫苗包括 COVID-19、流感、呼吸道合胞病毒、尖刺疫苗和 hMPV/PIV3 疫苗；潜在疫苗包括巨细胞病毒、EB 病毒、单纯疱疹病毒、水痘带状疱疹病毒和人类免疫缺陷病毒疫苗；公共卫生疫苗包括寨卡、尼帕、Mpox 疫苗；传染病疫苗包括莱姆病和诺如病毒疫苗。</p>
<h2>参考资料</h2>
<ul>
<li>五只比 Moderna 更受欢迎的股票</li>
<li>3 只股票，保护您的投资组合免受冠状病毒传播的影响</li>
<li>Biohaven 股价因药物试验结果飙升：是时候入场了吗？</li>
<li>什么是盈利报告？</li>
<li>AMD 对 NVIDIA 构成合法威胁吗？投资者应该关注什么</li>
<li>什么是道·琼斯狗策略？概述和示例</li>
<li>诺和诺德的挫折不会持续：一种改变游戏规则的药物出现</li>
</ul>
<p><strong>想了解其他对 Moderna 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Moderna, Inc. (NASDAQ: MRNA - 免费报告) 的最新 13F 申报和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ"/></p>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 比尔·盖茨的下一个重大人工智能赌注：星门（来自 Brownstone Research）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTkw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTkw"/></p>
<h2>您现在是否应该投资$1,000 购买 Moderna 股票？</h2>
<p>在考虑购买 Moderna 股票之前，您可能需要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Moderna 并不在其中。</p>
<p>尽管 Moderna 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MRNA

<p>Ensign Peak Advisors Inc 在第二季度减持 Moderna, Inc.（纳斯达克股票代码：MRNA）的持股比例，减持了 52.3%，出售了 80,198 股。在这次出售后，该公司持有 73,064 股，价值约 676,000 美元。其他机构投资者也调整了他们在 Moderna 的持仓。最近对该股票的分析师评级褒贬不一，有多次降级，共识评级为 “持有”。Moderna 的股票表现显示市值为 500 亿美元，每股收益为-4.08 美元</p>

<p>Ensign Peak Advisors Inc lessened its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 52.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 73,064 shares of the company's stock after selling 80,198 shares during the quarter. Ensign Peak Advisors Inc's holdings in Moderna were worth $8,676,000 at the end of the most recent quarter.</p>
<ul>
<li>3 Beaten-Down Stocks Ready for a Comeback</li>
</ul>
<div class="lb-trans"><p>Ensign Peak Advisors Inc 在第二季度减持了 Moderna, Inc.（纳斯达克股票代码: MRNA - 免费报告）的持股比例，根据最近提交给证券交易委员会的文件显示，该公司持有该公司股票 73,064 股，较上一季度减持了 80,198 股。Ensign Peak Advisors Inc 在最近季度结束时持有的 Moderna 股份价值 867.6 万美元。</p>
<ul>
<li>3 支备受打击的股票准备复苏</li>
</ul>
</div><p>Several other institutional investors have also bought and sold shares of MRNA. Hobbs Group Advisors LLC purchased a new position in shares of Moderna during the 4th quarter valued at $664,000. Illinois Municipal Retirement Fund lifted its holdings in Moderna by 22.1% during the first quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company's stock valued at $5,519,000 after purchasing an additional 9,360 shares during the last quarter. Swedbank AB bought a new position in Moderna during the first quarter worth about $3,315,000. Wellington Management Group LLP increased its stake in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company's stock worth $718,584,000 after purchasing an additional 1,614,460 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Moderna in the first quarter valued at approximately $2,693,000. Hedge funds and other institutional investors own 75.33% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者也买入和卖出了 MRNA 的股票。Hobbs Group Advisors LLC 在第四季度购入了 Moderna 的新头寸，价值 66.4 万美元。伊利诺伊州市政退休基金在第一季度增持了 Moderna 的持股比例 22.1%。伊利诺伊州市政退休基金现在持有该公司股票 51,791 股，价值 551.9 万美元，较上一季度增持了 9,360 股。瑞典银行 AB 在第一季度购入了 Moderna 的新头寸，价值约 331.5 万美元。惠灵顿管理集团 LLP 在第四季度增持了 Moderna 的股份 28.8%。惠灵顿管理集团 LLP 现在持有该公司股票 7,225,579 股，价值 7.19 亿美元，较上一季度增持了 1,614,460 股。最后，洛杉矶资本管理有限责任公司在第一季度购入了 Moderna 的新股份，价值约 269.3 万美元。对冲基金和其他机构投资者拥有该公司股份的 75.33%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和下调</h2>
</div><p>MRNA has been the subject of a number of recent research reports. Jefferies Financial Group lowered shares of Moderna from a &#34;buy&#34; rating to a &#34;hold&#34; rating and reduced their price objective for the company from $120.00 to $65.00 in a research note on Friday, September 13th. JPMorgan Chase &amp; Co. cut Moderna from a &#34;neutral&#34; rating to an &#34;underweight&#34; rating and reduced their price target for the company from $88.00 to $70.00 in a research report on Friday, September 13th. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a &#34;neutral&#34; rating for the company in a research note on Friday, September 13th. Oppenheimer cut Moderna from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a &#34;sell&#34; rating to a &#34;hold&#34; rating and cut their price objective for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Moderna presently has an average rating of &#34;Hold&#34; and a consensus price target of $100.44.</p>
<ul>
<li>Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity</li>
</ul>
<div class="lb-trans"><p>MRNA 近期成为多份研究报告的主题。杰富瑞金融集团将 Moderna 的股票评级从 “买入” 下调至 “持有”，并将公司的目标股价从 120.00 美元降至 65.00 美元。摩根大通将 Moderna 的评级从 “中性” 下调至 “减持”，并将公司的目标股价从 88.00 美元降至 70.00 美元。美国银行将 Moderna 的目标股价从 130.00 美元降至 110.00 美元，并为该公司设定了 “持有” 评级。Oppenheimer 将 Moderna 的评级从 “表现优异” 下调至 “市场表现”，德意志银行将 Moderna 的股票评级从 “卖出” 上调至 “持有”，并将公司的目标股价从 85.00 美元降至 80.00 美元。两位投资分析师给该股票评定了卖出评级，十三位分析师给予持有评级，四位分析师给予买入评级。根据 MarketBeat.com 的数据，Moderna 目前的平均评级为 “持有”，股票的共识目标价为 100.44 美元。</p>
<ul>
<li>Moderna 最近的下跌：看涨者看到机会</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on MRNA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MRNA 的最新分析</strong></p>
</div><h2>Moderna Stock Performance</h2>
<div class="lb-trans"><h2>Moderna 股票表现</h2>
</div><p>Shares of NASDAQ MRNA opened at $63.94 on Wednesday. The stock's 50-day moving average is $87.70 and its 200 day moving average is $110.43. The stock has a market cap of $24.50 billion, a price-to-earnings ratio of -4.08 and a beta of 1.67. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.</p>
<ul>
<li>GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?</li>
</ul>
<div class="lb-trans"><p>纳斯达克 MRNA 股票周三开盘价为 63.94 美元。该股票的 50 天移动平均价格为 87.70 美元，200 天移动平均价格为 110.43 美元。该股票的市值为 245 亿美元，市盈率为-4.08，β系数为 1.67。Moderna, Inc.的一年最低价为 62.55 美元，最高价为 170.47 美元。该公司的流动比率为 4.09，速动比率为 3.92，负债权益比为 0.05。</p>
<ul>
<li>GeoVax Labs：这家微型生物技术公司是繁荣还是衰败？</li>
</ul>
</div><p>Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts' consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the business posted ($3.62) EPS. The business's quarterly revenue was down 29.9% on a year-over-year basis. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Moderna（纳斯达克股票代码: MRNA - 获取免费报告）最近公布了其截至 8 月 1 日星期四的季度财报。公司报告称，该季度每股亏损 3.33 美元，超过分析师预期的 3.47 美元，增加了 0.14 美元。Moderna 的净利润率为-116.18%，净资产收益率为-21.35%。该季度，公司营收为 2.41 亿美元，而分析师预计为 1.2841 亿美元。与去年同期相比，公司季度营收同比下降了 29.9%。卖方分析师预计，Moderna, Inc.在本财年将实现每股盈利-9.52 美元。</p>
</div><h2>Insider Buying and Selling at Moderna</h2>
<div class="lb-trans"><h2>Moderna 内部人员的买卖行为</h2>
</div><p>In other news, President Stephen Hoge sold 15,000 shares of the business's stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the completion of the sale, the president now owns 1,442,089 shares of the company's stock, valued at approximately $174,665,819.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO James M. Mock sold 689 shares of the firm's stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the company's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares of the company's stock, valued at $174,665,819.68. The disclosure for this sale can be found here. Insiders sold a total of 78,158 shares of company stock worth $9,259,012 over the last three months. Company insiders own 15.70% of the company's stock.</p>
<div class="lb-trans"><p>另外，总裁 Stephen Hoge 于 7 月 15 日星期一出售了 15,000 股公司股票。股票的平均价格为 121.12 美元，总价值为 1,816,800.00 美元。完成交易后，总裁现在持有该公司股票 1,442,089 股，价值约 1.75 亿美元。该交易已在提交给 SEC 的文件中披露，可通过此超链接查看。此外，首席财务官 James M. Mock 于 7 月 8 日星期一出售了 689 股公司股票。股票的平均价格为 118.24 美元，总价值为 81,467.36 美元。交易完成后，首席财务官现在持有公司 7,269 股股票，价值 85.9 万美元。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。此外，总裁 Stephen Hoge 于 7 月 15 日星期一出售了 15,000 股公司股票。股票的平均价格为 121.12 美元，总交易额为 1,816,800.00 美元。交易完成后，总裁现在持有该公司股票 1,442,089 股，价值 1.75 亿美元。此次交易的披露可在此处找到。内部人士在过去三个月内共出售了总值 925.9 万美元的 78,158 股公司股票。公司内部人士持有公司股份的比例为 15.70%。</p>
</div><h2>About Moderna (Free Report)</h2>
<div class="lb-trans"><h2>关于 Moderna（免费报告）</h2>
</div><p>Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.</p>
<div class="lb-trans"><p>Moderna, Inc.是一家生物技术公司，致力于发现、开发和商业化信使 RNA 治疗药物和疫苗，用于治疗传染病、免疫肿瘤学、罕见疾病、自身免疫性疾病和心血管疾病，在美国、欧洲和国际市场均有业务。其呼吸道疫苗包括 COVID-19、流感、呼吸道合胞病毒、尖刺疫苗和 hMPV/PIV3 疫苗；潜在疫苗包括巨细胞病毒、EB 病毒、单纯疱疹病毒、水痘带状疱疹病毒和人类免疫缺陷病毒疫苗；公共卫生疫苗包括寨卡、尼帕、Mpox 疫苗；传染病疫苗包括莱姆病和诺如病毒疫苗。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Moderna</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>Biohaven Stock Soars on Drug Trial Results: Time to Jump In?</li>
<li>What are earnings reports?</li>
<li>Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li>
</ul>
<div class="lb-trans"><h2>参考资料</h2>
<ul>
<li>五只比 Moderna 更受欢迎的股票</li>
<li>3 只股票，保护您的投资组合免受冠状病毒传播的影响</li>
<li>Biohaven 股价因药物试验结果飙升：是时候入场了吗？</li>
<li>什么是盈利报告？</li>
<li>AMD 对 NVIDIA 构成合法威胁吗？投资者应该关注什么</li>
<li>什么是道·琼斯狗策略？概述和示例</li>
<li>诺和诺德的挫折不会持续：一种改变游戏规则的药物出现</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding MRNA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).</p>
<div class="lb-trans"><p><strong>想了解其他对 Moderna 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Moderna, Inc. (NASDAQ: MRNA - 免费报告) 的最新 13F 申报和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MRNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Bill Gates’s Next Big AI Bet: Stargate (From Brownstone Research)(Ad)</p>
<div class="lb-trans"><p>→ 比尔·盖茨的下一个重大人工智能赌注：星门（来自 Brownstone Research）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTkw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9590&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Moderna right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 购买 Moderna 股票？</h2>
</div><p>Before you consider Moderna, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Moderna 股票之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Moderna 并不在其中。</p>
</div><p>While Moderna currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Moderna 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ensign Peak Advisors Inc 出售了 80,198 股 Moderna 公司（纳斯达克股票代码：MRNA）